文献速递流行病学与生物统计临床试验与 GCP

α受体阻滞剂治疗输尿管结石:系统综述与荟萃分析

Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2016-12-01

该系统综述与荟萃分析纳入55项随机对照试验,评估α受体阻滞剂治疗输尿管结石的疗效与安全性。α受体阻滞剂促进结石排出的风险比为1.49(95%CI 1.39至1.61),中等质量证据;较大结石患者获益更明显(RR 1.57,95%CI 1.17至2.27),较小结石患者似乎无获益(RR 1.19,95%CI 1.00至1.48)。α受体阻滞剂缩短排石时间、减少疼痛发作、降低手术干预和住院风险,严重不良事件风险与对照组相似。

要点

  • α受体阻滞剂促进输尿管结石排出(RR 1.49,95%CI 1.39至1.61),中等质量证据。
  • 较大结石患者排石风险较对照高57%(RR 1.57,95%CI 1.17至2.27),较小结石似乎无获益。
  • α受体阻滞剂缩短排石时间、减少疼痛发作、降低手术和住院风险,严重不良事件风险相似。

核心结论

  • α受体阻滞剂似乎对适合保守治疗的输尿管结石患者有效,较大结石患者获益可能最大。
  • 这些结果支持现行指南推荐α受体阻滞剂在输尿管结石患者中发挥作用。

研究设计与样本

  • 系统综述与荟萃分析,检索Cochrane对照试验中心注册库、Web of Science、Embase、LILACS和Medline数据库及科学会议摘要至2016年7月。
  • 纳入比较α受体阻滞剂与安慰剂或对照治疗输尿管结石的随机对照试验,共纳入55项随机对照试验。
  • 两名团队成员独立提取每项纳入研究的数据,主要结局为结石排出患者比例,采用profile likelihood随机效应模型计算汇总风险比和95%置信区间。
  • 使用Cochrane协作组偏倚风险评估工具和GRADE方法评价证据质量并总结结论。
  • 系统综述注册号:PROSPERO CRD42015024169。

主要发现

  • α受体阻滞剂促进输尿管结石排出(RR 1.49,95%CI 1.39至1.61),中等质量证据。
  • 基于先验亚组分析,较小输尿管结石患者接受α受体阻滞剂似乎无获益(RR 1.19,95%CI 1.00至1.48)。
  • 较大结石患者接受α受体阻滞剂后结石排出风险较对照高57%(RR 1.57,95%CI 1.17至2.27)。
  • α受体阻滞剂效应与结石位置无关:上段或中段结石RR 1.48(95%CI 1.05至2.10),下段结石RR 1.49(95%CI 1.38至1.63)。
  • 与对照相比,接受α受体阻滞剂的患者排石时间显著缩短(均数差-3.79天,95%CI -4.45至-3.14;中等质量证据),疼痛发作次数减少(-0.74次,95%CI -1.28至-0.21;低质量证据),手术干预风险降低(RR 0.44,95%CI 0.37至0.52;中等质量证据),住院风险降低(RR 0.37,95%CI 0.22至0.64;中等质量证据);严重不良事件风险两组相似(RR 1.49,95%CI 0.24至9.35;低质量证据)。

关键数值与推荐

  • α受体阻滞剂促进结石排出的汇总风险比为1.49(95%CI 1.39至1.61),中等质量证据。
  • 较小结石患者亚组风险比为1.19(95%CI 1.00至1.48),较大结石患者亚组风险比为1.57(95%CI 1.17至2.27)。
  • 上段或中段结石风险比为1.48(95%CI 1.05至2.10),下段结石风险比为1.49(95%CI 1.38至1.63)。
  • 排石时间均数差为-3.79天(95%CI -4.45至-3.14),疼痛发作次数均数差为-0.74次(95%CI -1.28至-0.21),手术干预风险比为0.44(95%CI 0.37至0.52),住院风险比为0.37(95%CI 0.22至0.64),严重不良事件风险比为1.49(95%CI 0.24至9.35)。

临床怎么用

  • α受体阻滞剂似乎对适合保守治疗的输尿管结石患者有效,较大结石患者获益可能最大。
  • 这些结果支持现行指南推荐α受体阻滞剂在输尿管结石患者中发挥作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy and safety of alpha blockers in the treatment of patients with ureteric stones. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Cochrane Central Register of Controlled Trials, Web of Science, Embase, LILACS, and Medline databases and scientific meeting abstracts to July 2016. REVIEW METHODS: Randomized controlled trials of alpha blockers compared with placebo or control for treatment of ureteric stones were eligible. : Two team members independently extracted data from each included study. The primary outcome was the proportion of patients who passed their stone. Secondary outcomes were the time to passage; the number of pain episodes; and the proportions of patients who underwent surgery, required admission to hospital, and experienced an adverse event. Pooled risk ratios and 95% confidence intervals were calculated for the primary outcome with profile likelihood random effects models. Cochrane Collaboration's tool for assessing risk of bias and the GRADE approach were used to evaluate the quality of evidence and summarize conclusions. RESULTS: 55 randomized controlled trials were included. There was moderate quality evidence that alpha blockers facilitate passage of ureteric stones (risk ratio 1.49, 95% confidence interval 1.39 to 1.61). Based on a priori subgroup analysis, there seemed to be no benefit to treatment with alpha blocker among patients with smaller ureteric stones (1.19, 1.00 to 1.48). Patients with larger stones treated with an alpha blocker, however, had a 57% higher risk of stone passage compared with controls (1.57, 1.17 to 2.27). The effect of alpha blockers was independent of stone location (1.48 (1.05 to 2.10) for upper or middle stones; 1.49 (1.38 to 1.63) for lower stones). Compared with controls, patients who received alpha blockers had significantly shorter times to stone passage (mean difference -3.79 days, -4.45 to -3.14; moderate quality evidence), fewer episodes of pain (-0.74 episodes, -1.28 to -0.21; low quality evidence), lower risks of surgical intervention (risk ratio 0.44, 0.37 to 0.52; moderate quality evidence), and lower risks of admission to hospital (0.37, 0.22 to 0.64; moderate quality evidence). The risk of a serious adverse event was similar between treatment and control groups (1.49, 0.24 to 9.35; low quality evidence). CONCLUSIONS: Alpha blockers seem efficacious in the treatment of patients with ureteric stones who are amenable to conservative management. The greatest benefit might be among those with larger stones. These results support current guideline recommendations advocating a role for alpha blockers in patients with ureteric stones. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration No CRD42015024169.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016. PMID: 27908918. doi:10.1136/bmj.i6112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。